Side Effects

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.

By |2019-09-23T11:28:24-04:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

The Heart of the Matter: Cardiac Health for GIST Patients

The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To [...]

By |2019-09-20T15:37:59-04:00February 10th, 2016|GIST Education, Newsletter, Side Effects|

Regorafenib-Related Hand-Foot Skin Reaction

A recent comprehensive review of the literature of the PubMed database and of the clinical experiences of oncologists and dermatologists concerning patients with regorafenib (Stivarga) related hand-foot skin reaction (HFSR) was published in the [...]

By |2019-10-31T13:40:24-04:00June 26th, 2015|Coping with GIST, News, Side Effects|

Fatigue Reduction: Moving Towards a Better Future

As one of the most common side-effects of Gleevec, Sutent and Stivarga, fatigue is a condition that many GIST survivors are intimately acquainted with. The National Comprehensive Cancer Network defines cancer-related fatigue as “a [...]

By |2022-01-05T11:13:27-05:00April 7th, 2015|News, Side Effects|
Go to Top